Ayden Scheim is an Assistant Professor of Epidemiology at Drexel University's Department of Epidemiology and Biostatistics. He holds adjunct appointments at the Centre on Drug Policy Evaluation (St. Michael’s Hospital, Toronto) and Western University’s Department of Epidemiology and Biostatistics, and is a Visiting Professor at UCSF’s Center for AIDS Prevention Studies. His research focuses on social epidemiology, particularly intersections of stigma, policy, and healthcare inequities affecting LGBT communities and people who use drugs. He leads global studies on transgender health, including NIH-funded projects in India and Canada, and methodological work on measuring intersectional discrimination. Dr. Scheim earned a PhD in Epidemiology and Biostatistics from Western University (2017) and a BA in Sociology from the University of Toronto. His postdoctoral training at UC San Diego was supported by CIHR. His work emphasizes community-engaged research, including participatory surveys and interventions to improve healthcare access for marginalized groups. Research interests span global health, HIV/AIDS, substance use, and intersectional stigma. Key topics include transgender healthcare access, drug policy evaluation, and the impact of legal gender recognition on health outcomes. He collaborates internationally, with a focus on low/middle-income countries and transgender populations. His scientific awards include the Pierre Elliott Trudeau Foundation and Vanier Canada Graduate Scholarships, and a CIHR Fellowship. Recent publications address overdose mortality, drug checking services, and structural stigma’s impact on healthcare access for transgender individuals.
António O. S. S. Rangel is a Full Professor (Professor Catedrático) at the Escola Superior de Biotecnologia (ESB-UCP), University of Porto, Portugal. He serves as President of the Scientific Board of ESB-UCP and is a member of the Direction Board of the Research Center Centre for Biotechnology and Fine Chemistry (CBQF) . His academic journey includes a Bachelor's in Chemistry (1985) and a PhD in Biotechnology (1991) , both from the University of Porto. He has co-authored over 190 international journal papers and supervised 20 PhD theses. His research focuses on flow-based methods for automation and miniaturization of biochemical assays, with applications in environmental monitoring, food analysis, and biomedical diagnostics. Key projects include Aqua_Smart (toxic metal monitoring in aquatic systems) and HSoil4Food (soil health for food safety). His teaching spans general and analytical chemistry disciplines. Education: PhD in Biotechnology, ESB-UCP (1991) Agregação in Biotechnology, ESB-UCP (2014) Bachelor in Chemistry, University of Porto (1985) Selected Projects: STF-EDIH: Smart Sustainable Farms & Trade Hub (2023–2026) Aqua_Smart: Toxic Metals Monitoring (2023–2026) HSoil4Food: Healthy Soils for Healthy Foods (2021–2023) His work aligns with UN Sustainable Development Goals, particularly in advancing education and sustainable innovation through analytical methodologies. He actively contributes to editorial boards and international conferences, emphasizing flow injection analysis and microfluidic technologies.
Kristina Mach is a researcher at the Chair of Computer Science Applications in Medicine at the Technische Universität München (TUM) . She focuses on interdisciplinary projects combining computer science and medical applications, particularly in imaging and robotic assistance. Research area: Medical imaging, machine learning, and surgical robotics Key technologies: Deep learning, image registration, and generative adversarial networks Applications: Ophthalmic surgery, radiology reporting, and intraoperative OCT Her recent work includes SpecstatOR for iOCT segmentation, Multitask Weakly Supervised Networks for MR-US registration, and Flexr for few-shot chest X-ray classification. These projects emphasize interoperability between imaging modalities and structured reporting in clinical workflows.
Dr. Igor Chernyavsky is a Senior Lecturer in Applied Mathematics at the Department of Mathematics, The University of Manchester. His research focuses on complex living systems, particularly transport phenomena and biofluid dynamics in tissue physiology. He leads projects in continuum mechanics, mathematics in life sciences, and uncertainty quantification. His work contributes to UN Sustainable Development Goals through initiatives like Digital Futures, Christabel Pankhurst Institute, and Henry Royce Institute. Research interests include placental hemodynamics, biomimetic models, and multiscale modeling of biological systems. Key projects involve placental circulation modeling for stillbirth prediction, umbilical cord dynamics, and microfluidic studies of blood flow in porous media. He collaborates on placental imaging, bioreactor engineering, and clinical placentology. Recent publications highlight placental oxygenation, umbilical cord solute transfer, and robust fabrication of PDMS microcapsules mimicking red blood cells. His work bridges experimental and theoretical approaches, emphasizing clinical translation. He supervises PhD students and leads grants totaling £ millions, including Maternal & Fetal Health Research Centre (2018-2035) and ROBUST-BIOPRINT (2023-2025). He actively seeks collaborations in biomaterials, fluid dynamics, and biomedical engineering. Labs/teams: Continuum Mechanics Group, Mathematics in Life Sciences Team, and Uncertainty Quantification & Data Science Group.
Associate Professor Betty Chan is an Emergency Physician, Clinical Toxicologist, and clinical researcher at the University of New South Wales. She serves as Head of the Discipline of Critical Care at UNSW and Head of the Clinical Toxicology Unit at the Prince of Wales Hospital. Additionally, she works as a VMO toxicologist at the New South Wales Poisons Information Centre and serves on the editorial board of Clinical Toxicology and the SES LHD Human Research and Ethics Committee. Dr. Chan completed her Emergency Medicine training in 1990 and earned her PhD in toxicology from the University of Sydney in 1997. Her academic credentials include MBBS, FACEM, PhD, and MDiv. Her primary research interests focus on translational research in Clinical Toxicology, Harm Reduction, Antidotes, Medical Education, and the application of Artificial Intelligence in medical education. Specific areas of investigation include digoxin overdose management, dihydropyridine toxicity, methotrexate intoxication and antidotes, safe opioid use and prescription practices, development of clinical decision rules for non-traumatic CT head imaging, herbicide toxicity (including paraquat, bromoxynil, and MCPA), acute behavioral disturbance treatment, sodium channel blocker toxicity, lithium poisoning, cognitive assessment following overdose and shift work, tapentadol prescription trends and poisoning, and adherence to clinical guidelines for specific poisonings. Analysis of Dr. Chan's recent publications reveals a strong focus on clinical toxicology with particular emphasis on drug overdose management, antidote efficacy, and patient safety. Her work spans multiple areas including cardiovascular toxicology (digoxin, calcium channel blockers), hepatotoxicity (acetaminophen), neurotoxicology (anticholinergics, antipsychotics), and harm reduction strategies (naloxone distribution). Many of her studies are part of the Australian Toxicology Monitoring (ATOM) research program, demonstrating her commitment to evidence-based toxicology practice. 2016 John Gilroy Potts Award at the ACEM conference for the paper 'The Safety and Effectiveness of Droperidol for Sedation of Acute Behavioural Disturbance in the Emergency Department' 2019 Best Scientific presentation at the 39th Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) on 'Using EXTRIP criteria as indications for Extracorporeal Treatment in Lithium Poisoning.' As Head of the Discipline of Critical Care at UNSW, Dr. Chan leads the curriculum and teaching for medical students in Emergency Medicine, Anesthesia, and Intensive Care. She also oversees the teaching curriculum and supervision of toxicology registrars and fellows as head of the Clinical Toxicology Unit. Her research supervision includes ILP Honours projects focused on the Poisons Information Centre clinical Toxicology referral Study (PICTS) and adherence to clinical guidelines for specific poisonings. She has been principal investigator for numerous clinical research projects in toxicology, including the multi-center Australian Toxicology Monitoring (ATOM) Study initiated in 2013 and the Translational Australian Clinical Toxicology (TACT) program funded by NHMRC grants. Dr. Chan's work has significantly impacted clinical practice, particularly in demonstrating that patients with digoxin poisoning can be managed safely with small, titrated doses of digoxin antibody, and establishing guidelines for folinic acid use in methotrexate poisoning. Her research on cognitive impairment following sedative overdose has informed recommendations about post-overdose activity restrictions.
Eugenia Oviedo-Joekes is a Professor and Tier 1 Canada Research Chair in the School of Population and Public Health at the University of British Columbia's Faculty of Medicine. Her research focuses on substance use, person-centered care in addiction, injectable opioid agonist treatment, and harm reduction, with particular emphasis on psychosocial, sociocultural and behavioral determinants of health. Dr. Oviedo-Joekes obtained her degree in clinical psychology at the University of Cordoba (Argentina), a PhD in social psychology and behavioral sciences methodology in Spain, and completed post-doctoral studies at the Andalusian School of Public Health. She moved to Canada in 2006 to join Dr. Schechter's research program and became an Investigator on the NAOMI study, North America's first heroin-assisted treatment trial. She has led the SALOME study, testing injectable hydromorphone for opioid use disorder, and provided evidence to expand injectable opioid agonist treatment across Canada. Her recent research examines client preferences for treatment design, the impact of relaxing restrictions on take-home medications during the COVID-19 pandemic, and implementation of supervised injectable opioid treatment in diverse settings. Her work bridges clinical research with health policy to improve treatment access and quality for people with opioid use disorder, with publications spanning addiction medicine, public health, and health services research. Tier 1 Canada Research Chair in substance use treatment Leadership in major clinical trials including NAOMI and SALOME Development of person-centered approaches to addiction care Extensive publications on injectable opioid agonist treatment effectiveness Dr. Oviedo-Joekes supervises graduate students in Population and Public Health and collaborates with the Centre for Health Evaluation and Outcome Sciences and Providence Health Care Research Institute. Her work continues to shape evidence-based approaches to treating severe opioid use disorder in Canada and internationally.
Franz Wotawa is a Professor of Software Engineering at Graz University of Technology. He holds a M.Sc. (1994) and PhD (1996) from Vienna University of Technology. He has served as head of the Institute for Software Technology from 2003–2009 and since 2020. His research focuses on model-based reasoning, software testing, autonomous systems, and diagnosis, with over 390 peer-reviewed publications. He founded Softnet Austria (2006) to bridge research and industry. He leads the Christian Doppler Laboratory for Quality Assurance Methodologies for Autonomous Cyber-Physical Systems since 2017 and has supervised 90+ master and 36+ PhD students. His awards include the 2016 Lifetime Achievement Award from the International Diagnosis Community. He is a member of Academia Europaea, IEEE, and AAAI. **Education**: M.Sc. in Computer Science, Vienna University of Technology, 1994 PhD, Vienna University of Technology, 1996 **Research Interests**: Model-based reasoning, qualitative reasoning, theorem proving, mobile robotics, verification/validation, software testing/debugging, AI, and autonomous systems. **Notable Projects**: A-IQ Ready (2022–2026): Quantum sensing for autonomous systems. ALFA (2024–2027): AI for smart diagnosis in building automation. Bilateral AI (2024–2029): Combining symbolic and sub-symbolic AI. VARCOS (2025–2028): Vehicle-road cooperative systems for autonomous driving. **Awards & Memberships**: Lifetime Achievement Award (2016, International Diagnosis Community) Senior Member, AAAI Member of Academia Europaea, IEEE, ACM, and Austrian Computer Society **Labs/Teams**: Christian Doppler Laboratory for Quality Assurance Methodologies (since 2017). Active in Cluster of Excellence “Bilateral AI” at TU Graz.
Erika M. Summers, MD is a Clinical Associate Professor in the Department of Dermatology at the University of Utah. She directs both the Division of Cosmetic Dermatology and the University Inpatient Dermatology Service at the University of Utah and Huntsman Cancer Institute, specializing in laser/aesthetic, general, and medical dermatology with exceptional patient satisfaction (4.9/5 from 459 reviews). Her educational background includes: Undergraduate: B.S. in Biology, Magna Cum Laude, Georgetown University, College of Arts and Sciences Medical School: M.D., Summa Cum Laude, University of Maryland School of Medicine Residency: Internal Medicine, Beth Israel Deaconess Medical Center Residency: Dermatology, University of Utah Dr. Summers pioneers non-surgical cosmetic treatments using neuromodulators, fillers, and advanced lasers (fractional CO2, Fraxel, pulsed dye) for aging, acne scars, rosacea, and vascular conditions. Her medical dermatology expertise spans venous insufficiency, complex inpatient cases, and drug-induced eruptions in elderly patients, blending technical precision with compassionate care. Her publication record (2008-2021) reveals sustained focus on Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis, safety of cosmetic procedures post-isotretinoin, and cutaneous manifestations of systemic diseases through multicenter collaborations and clinical trials. Scientific recognition includes: Women’s Dermatologic Society Mentorship Award (2014) She trains dermatology residents in cosmetic injections/lasers and oversees inpatient care for life-threatening dermatologic conditions, mentoring through structured curriculum development and hands-on supervision. Her leadership extends to directing medical staff and aestheticians in the Cosmetic Dermatology division. Dr. Summers leads two integrated clinical teams: the Cosmetic Dermatology division delivering cutting-edge aesthetic treatments, and the University Inpatient Dermatology Service managing complex cases at Huntsman Cancer Institute, demonstrating exceptional operational and clinical leadership across outpatient and hospital settings.
Dr. Marc-André Roy is a Full Professor in the Department of Psychiatry and Neurosciences at the Faculty of Medicine, Université Laval. He serves as Director of the RAPPSoDIS Lab and CAP-Rétablissement Research Teams at the Centre de Recherche CERVO, and as Psychiatrist and Medical Director at the Clinique Notre-Dame des Victoires (Institut universitaire de Santé mentale de Québec). His work focuses on early psychosis intervention within a recovery-oriented framework, with particular expertise in schizophrenia treatment approaches and comorbid conditions. Dr. Roy completed his medical and psychiatric training at Laval University in 1991, followed by a three-year fellowship in epidemiology and genetics research on psychotic disorders at the University of Iowa with Drs. Nancy Andreasen and Raymond Crowe, and further training in genetic epidemiology at the Medical College of Virginia with Dr. Kenneth Kendler. Dr. Roy's research centers on innovative approaches to treating psychosis and schizophrenia, with emphasis on early intervention. He has been a pioneer in Quebec and Canada in early psychosis research since 1997. His work examines pharmacological treatments including long-acting injectable antipsychotics and clozapine in real-world settings, as well as non-pharmacological approaches like cognitive remediation. More recently, his research has expanded to address comorbid conditions such as gaming disorder, problem gambling, and cannabis use among individuals with psychosis. Analysis of Dr. Roy's recent publications reveals a strong focus on real-world treatment effectiveness, patient-centered decision making, and understanding comorbid conditions in early psychosis. His work increasingly incorporates digital health interventions and rapid-learning healthcare systems to improve early psychosis services. Key trends include examining the impact of specific medications (particularly aripiprazole), developing harm reduction strategies for substance use, and implementing recovery-oriented practices in clinical settings. Dr. Roy has received numerous prestigious awards for his contributions to psychiatry: Robert W Kerwin prize (2024) for the best article in psychopharmacology published in 2022 Heinz E. Lehmann Excellence in Psychiatry prize (2020) Prix Hippocrate (2015) acknowledging physicians and pharmacists' collaboration First award for the book "Je suis une personne, pas une maladie" (2014) First award for the project "Anxiety disorders and psychosis" (2011) Dr. Roy has supervised over 20 graduate students and psychiatric residents across various disciplines. His research has been supported by multiple funding agencies, including the Canadian Institutes of Health Research. He leads the FRQ-SC CAP-Recovery Research Group, which focuses on understanding, acting, and sharing to support the recovery of people living with psychotic disorders. Through the RAPPSoDIS Lab, he conducts innovative research on optimizing treatment approaches for psychosis in real-world settings. Dr. Roy directs the Clinique Notre-Dame des Victoires, an early intervention program for young adults with psychotic disorders that emphasizes recovery-based interventions and family collaboration. The program involves a multidisciplinary team including psychiatrists, nurses, pharmacists, psychologists, social workers, and other healthcare professionals working together to provide comprehensive care.
Roger Mortimer, MD, is a Professor of Family Medicine at the University of California, San Francisco (UCSF), practicing at UCSF Fresno. He serves as Associate Chief of the UCSF Fresno Family & Community Medicine Department and Assistant Dean for Academic Affairs at UCSF Fresno. Dr. Mortimer also holds key roles in wilderness and rescue medicine, including Instructor for the National Cave Rescue Commission and delegate to the International Commission on Alpine Rescue (ICAR). Education & Training: BA in Biology and Psychology, UC Berkeley (1986) MD, University of Sherbrooke, Quebec (1991) Residency in Family Medicine, UCSF Fresno (1994) Diversity, Equity, and Inclusion Champion Training, UCSF (2021) Research Interests: Dr. Mortimer's research bridges HIV medicine and wilderness medicine. His HIV-focused work explores fungal infections in immunocompromised patients, particularly Coccidioides immitis . In wilderness medicine, he investigates suspension syndrome—a potentially fatal condition from prolonged harness use during climbing or rescue operations. His work informs evidence-based protocols for mountain rescue teams worldwide. Clinical Practice: He provides primary and HIV specialty care at the CRMC Special Services Clinic, supervises residents at Community Regional Medical Center, and mentors trainees across UCSF Fresno. Awards & Honors: UCSF Fresno Faculty Research Award (2013) Fellow, American Academy of Family Physicians (2014) Fellow, Academy of Wilderness Medicine (2017) Dr. Alex Moir Award for Inspirational Character and Mentorship (2020) UCSF Fresno Family & Community Medicine Faculty of the Year (2025) Wilderness Medicine Leadership: Assistant Training Officer, Fresno County Sheriff’s Search & Rescue Mountaineering Team Instructor, National Cave Rescue Commission NCRC Delegate to ICAR (International Commission on Alpine Rescue)
Richard Garfein is an Adjunct Professor in the Herbert Wertheim School of Public Health & Human Longevity Science at San Diego State University. He holds a BA in Biology from the University of California Santa Barbara (1985), an MPH in Epidemiology from San Diego State University (1989), and a PhD in Infectious Disease Epidemiology from Johns Hopkins University (1997). His research focuses on infectious diseases, particularly tuberculosis (TB), HIV/AIDS, and hepatitis C, with an emphasis on vulnerable populations such as people who inject drugs, migrants, and marginalized communities. Garfein’s work spans epidemiological studies, intervention development, and policy analysis. He has led multiple NIH-funded studies investigating innovative TB treatment strategies (e.g., video-observed therapy), cross-border health dynamics, and the impact of drug policies on public health. He has also contributed to studies on the epidemiology of HIV and HCV among methamphetamine users and the role of harm reduction strategies in mitigating disease transmission. His research often integrates digital health tools, such as mobile phone-based monitoring, to improve adherence to treatments and surveillance of infectious diseases. Notable projects include studying the effects of Mexico’s drug policy reforms, the impact of supervised consumption sites on disease transmission, and wastewater-based epidemiology for tracking SARS-CoV-2 variants. Garfein has collaborated with institutions like UCSD, the Altman Clinical and Translational Research Institute, and international teams to address global health challenges. His grants include NIH awards for studies on TB diagnostics, drug tourism’s impact on infection rates, and mobile health interventions for treatment adherence.
Dan Small is an Honorary Research Associate in the Department of Anthropology at the University of British Columbia. He holds a PhD in medical anthropology from UBC, an MPhil in circumpolar studies from the University of Cambridge, and dual undergraduate degrees in sociology/anthropology and psychology from Simon Fraser University (both with first-class honours). His work focuses on harm reduction, healthcare culture, and marginalized populations, with a particular emphasis on supervised injection facilities and systemic barriers to healthcare access. Dr. Small has developed and evaluated initiatives such as social enterprises, housing programs, and healthcare services for vulnerable communities. His role in establishing Insite, North America’s only supervised injection facility, involved navigating complex socio-political challenges. He also contributed to medical regulation through roles with the College of Physicians and Surgeons of BC and the Medical Council of Canada. His research interests include medical ethics, peer-to-peer regulation, therapeutic narratives, and globalization’s impact on health. He has taught in anthropology and sociology, emphasizing critical approaches to healthcare and social justice. Scientific Awards and Achievements: Dr. Small has received prestigious awards including the UBC Canadian Airlines Travel Prize (1998), Queen Elizabeth II Centennial Scholarship (1996), and multiple SSHRC fellowships. His work bridges academic research and activism, advocating for evidence-based policies that prioritize marginalized communities. Advising and Grants: While specific grants are not detailed, his extensive involvement in program development and policy advocacy highlights his leadership in securing resources for harm reduction initiatives. He actively collaborates with interdisciplinary teams to advance healthcare equity. Labs/Teams: Central to his work is the interdisciplinary collaboration with the Insite team and community organizations in Vancouver’s Downtown Eastside. His research often integrates participatory methods, ensuring marginalized voices shape policy and practice.
Dr Carol-Ann Getty is a Research Fellow at the National Addiction Centre within the Department of Addictions Sciences at King's College London's Institute of Psychiatry, Psychology & Neuroscience (IoPPN). She currently holds an Academic Fellowship from the Society for the Study of Addiction (SSA) and has been at King's since 2017, initially undertaking an SSA-funded PhD. Her research focuses on the development and evaluation of digitally delivered Contingency Management (CM) behavioral interventions for individuals with substance use disorders. Dr Getty's work specifically explores how mobile and digital platforms can increase the accessibility, engagement, and effectiveness of evidence-based CM approaches within real-world addiction services. As part of her Fellowship, she is developing and evaluating a smartphone app to remotely monitor heroin use and incentivize abstinence in service users with heroin dependence. Dr Getty has contributed to several NIHR-funded research projects evaluating CM interventions aimed at improving adherence to supervised opioid agonist treatment, increasing naloxone carriage, and supporting continuity of care for individuals with a history of heroin use transitioning from prison to the community. Prior to joining King's, she worked at the Behavioural Research Unit at Johns Hopkins University in Baltimore on CM studies related to substance dependence treatment outcomes, medication adherence in HIV patients, and reducing HIV-related risk behaviors among people who inject drugs. SSA Academic Fellowship - Primary Investigator (2023-2026) CM4COYN Project - Co-Investigator (2025-2026) Drugs Research Group member CM4OUD, TIES, PRET research initiatives In addition to her research, Dr Getty co-leads the 'Contemporary Issues and Theories in Addiction Science' module on KCL's BSc Psychology programme and supervises MSc students on the Addictions programme at KCL. She also serves as a co-organizer and committee member for the SSA's annual conference and on the communications and events committee for the SSA.
Dr. Ashley Wood is a Senior Lecturer and Director of Learning and Teaching at the School of Optometry and Vision Sciences, Cardiff University. An experienced optometrist and Cardiff graduate, Dr. Wood has been with the institution since 2012, contributing significantly to both research and teaching in the field of vision sciences. Dr. Wood's educational background includes a BSc in Optometry & Vision Science (2003-2006) and a PhD in "Retinal structure and function in Age-related Maculopathy" (2007-2011), both from Cardiff University. Professional credentials include Fellowship of the Higher Education Academy (FHEA), Accreditation for Eye Health Examination Wales (EHEW), and registration as an Optometrist with the General Optical Council (GOC: 01-32560). Research interests focus primarily on age-related macular degeneration (AMD), the leading cause of vision loss in the EU/UK. Dr. Wood employs objective assessment methods including Optical Coherence Tomography (OCT), ocular electrophysiology, and retinal imaging densitometry. Current work involves using a prototype long wavelength OCT device that enables visualization of the choroid, a layer of blood vessels beneath the retina not visible with standard OCT devices. This technology also allows retinal imaging under dark-adapted conditions, facilitating studies of physiological and pathological changes in the dark-adapted eye. Dr. Wood has secured significant research funding including a Macular Society PhD Studentship (£99,858), AltRegen Ltd. Clinical Trial (£1.2M), and multiple studentships from the College of Optometrists and Abbeyfield Research Foundation. Current research projects focus on improving AMD detection and monitoring to ultimately support better treatments and prevent vision loss. Scientific contributions include numerous publications on AMD detection, OCT imaging, and electrophysiological assessment. Key awards and recognitions include multiple CUROP Summer Studentships, Abbeyfield Research Foundation PhD Studentship, and ISCEV Travel Award. Teaching responsibilities are extensive, including leadership of the Investigative Optometry and Case Studies module (OP3206) and Abnormal Ocular Conditions module (OP3104). Dr. Wood also delivers color vision lectures, supports clinical sessions, and supervises research projects. International teaching experience includes collaboration with HU University of Applied Sciences in Utrecht, Netherlands for the "Eye Care and Diabetes; the Bigger Picture" summer school. Administrative roles include serving as Director of Learning and Teaching, Exams Liaison Officer, and chairing the Student-Staff Panel. Dr. Wood currently supervises multiple postgraduate students working on AMD-related research projects.
Professor H. Nesrin DİLBAZ is a prominent academic at Üsküdar University, specializing in Psychiatry and Behavioral Neuroscience. She holds a professorship and has been actively involved in research and clinical practice since the 1990s. Born in 1958, she graduated from Anadolu University Faculty of Medicine in 1984 and completed her Adult Psychiatry specialization in 1991. Her career includes roles as a Psychiatric Specialist, Associate Professor, and AMATEM Director at Ankara Numune Hospital between 1991–2004. Her research focuses on addiction medicine, neuromodulation, neuroimaging, and social psychology. Notable projects include the Collaborative Outcomes study (COH-FIT) on pandemic impacts and the Neuroscience20 initiative. She has supervised over 14 graduate theses on topics like social media addiction, substance use disorders, and psychological resilience. Her publications span behavioral neuroscience, psychiatric comorbidities, and pandemic mental health. She has contributed to international collaborations and authored textbooks on addiction treatment. Key recent work addresses synthetic cannabinoid disorders and HCV prevalence among drug users.
